Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Massachusetts based CEO’ operating in the Biotechnology space. If you think a CEO’ is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Richard Terry
CEO, CTO and Founder of Harton Therapeutics
For more than 15 years, Richard Terry has led cross-functional teams in the development of innovative and novel technologies. His unique background in aerospace engineering, physics and biochemistry is a testament to his ability to transcend barriers and bring together a diverse set of resources to achieve the impossible. Richard’s research interests include applying systems-level engineering to biological challenges, and he is a prominent expert in synthetic biology. Prior to launching ReadCoor, Richard was Lead Senior Staff Scientist at Harvard University’s Wyss Institute for Biologically Inspired Engineering. At the Wyss, he supported advancements in reading, writing and editing nucleic acid, better known as nucleic acid sequencing, gene synthesis, and gene editing. Richard was one of the institute’s first hires and joined the founding team before the research center opened its doors. He built and transformed the Synthetic Biology group from its earliest form into the world-renowned Translational Synthetic Biology group that it is today. A sample of the tools developed by the Synthetic Biology group under his charge includes Ultra-Long DNAs, Next Gen Sequencing, Nanopore Sequencing, Multiplexed Automated Genome Engineering (MAGE), Programmable DNA Nanotherapeutic Robotic Device, CRISPR, TALEN, Zinc Finger, CADnano, SeqTag, Data Encoding and Enzymatic Synthesis of DNA.
Follow Richard Terry:
About Harton Therapeutics, Harvard Medical School: Harton is a biotechnology platform company pioneering the next revolution in personalized immune therapies to treat each and every patient.
Yingshuang Chai
Co-Founder & CEO of NuProbe
Yingshuang Chai is a Co-Founder, CEO, and Chairman of the Board of Directors at NuProbe.
Follow Yingshuang Chai:
About NuProbe: An early stage molecular diagnostics company.
Chris Mirabelli
President & CEO of Leap Therapeutics
Dr. Mirabelli has served as the Chairman of our Board of Directors since 2016 and has also served as our President and Chief Executive Officer since our inception in 2011. Dr. Mirabelli has been a managing director of HealthCare Ventures LLC since 2000. From December 1999 to May 2000, Dr. Mirabelli served as president of pharmaceutical research and development and member of the board of directors of Millennium Pharmaceuticals, Inc., following its merger with LeukoSite Inc., where Dr. Mirabelli had been serving as president, chief executive officer and chairman of the board of directors since 1993. He was a co-founder of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), where he held several positions including senior vice president of research, from 1989 until 1993. Dr. Mirabelli started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) R&D Division. He is a member of the board of advisors of the Blavatnik Biomedical Accelerator Fund at Harvard Medical School and the Boston Biomedical Innovation Center. Dr. Mirabelli is a member of the Board of Trustees of Guilford College. He received his Ph.D. in molecular pharmacology from Baylor College of Medicine and a B.S. degree in biology from State University of New York at Fredonia.
Follow Chris Mirabelli:
About Leap Therapeutics: Leap Therapeutics is a clinical-stage biopharmaceutical company.
Paul Chang
President, CEO/CSO and Lead Founder of ARase Therapeutics
Follow Paul Chang:
About ARase Therapeutics: Arase Therapeutics is a science-focused oncology company developing therapies that modulate cancer-relevant cell signaling pathways.
Rachel E. Haurwitz
Co-founder, President & CEO of Caribou Biosciences
Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
Follow Rachel E. Haurwitz:
About Caribou Biosciences: Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Noubar Afeyan
Founder & CEO of Flagship Pioneering
Noubar Afeyan is Founder, Senior Managing Partner and Chief Executive Officer at Flagship Ventures, a leading early stage venture capital firm. Noubar also leads the firm’s VentureLabs unit that invents and launches transformative startups. Noubar is a Senior Lecturer at MIT’s Sloan School of Management where he has taught courses on technology-entrepreneurship, innovation and leadership since 2000. Noubar lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation and venture capital to biological engineering, drug discovery, medical technologies and renewable energy. During his 28-year career as inventor, entrepreneur, CEO and venture capitalist, Noubar has co-founded and helped build over 35 successful life science and technology startups. Noubar was Founder and Chief Executive Officer at PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive’s acquisition by Perkin Elmer/Applera Corporation in 1998, Noubar was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently Noubar serves on a number of public and private company boards including CiBO Technologies, Epiva BioSciences, Evelo BioSciences, Joule Unlimited, Kaleido BioSciences, Moderna Therapeutics, Pronutria Biosciences and Seres Therapeutics. Previously, Noubar was a Member of the founding team, Director and Investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Affinnova (acquired by AC Nielsen). Noubar received a Technology Pioneer 2012 award from the World Economic Forum in recognition of the breakthrough solar fuel technology being developed at Joule Unlimited. Noubar has served as Chairman of the Global Agenda Council on Chemicals, Advanced Materials and Biotechnology of the World Economic Forum as well as being a member of the Meta-Council on Emerging Technologies. Noubar is a Member of the Board of Overseers of the Boston Symphony Orchestra. In addition, he serves on the board of AmeriaBank and of UWC Dilijan International School, both of Armenia. Previously, Noubar was a Co-Founder and Member of the Board of Directors at National Competitiveness Foundation of Armenia, a private-public partnership dedicated to promoting economic development in the former Soviet Republic of Armenia. In 2008 Noubar received the Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as United States citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. Noubar has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.
Follow Noubar Afeyan:
About BIND Therapeutics, Cogen Therapeutics, Cygnal Therapeutics, Ensemble Therapeutics, Flagship Pioneering, Generate Biomedicines, Harvard Business School, Indigo, Joule Unlimited Technologies, Laronde, Massachusetts Institute of Technology, Moderna Therapeutics, Omega Therapeutics, Permeon Biologics, Ring Therapeutics, Rubius Therapeutics, Seres Therapeutics: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Simba Gill
President & CEO of Evelo Biosciences
Simba Gill, PhD is an entrepreneur, investor and CEO who believes passionately that science and globalization will dramatically improve life in the 21st century. Dr. Gill is currently the CEO of Evelo, Sr. Partner at Flagship Ventures, and Executive Chair of Blackfynn. Dr. Gill founded or had lead roles in moksha8, Epirus, Maxygen, Verdia, Avidia, Codexis, Systemix and Valentis, four of these companies have been taken public and three were acquired through strategic trade sales. Exit valuations were between $400M – $6B. Dr. Gill has also led, built and launched several commercial businesses/products generating annual revenues of between $150M-$2B. Dr. Gill has founded and/or had lead roles in pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, immunodiagnostics and the cancer microbiome. He has also been an investor, advisor, founder and CEO of several emerging market life science companies. Dr. Gill was a Partner at TPG, focused on investments in Life Sciences and Emerging Markets. Early in his career, Dr. Gill was co-head of Worldwide Marketing for Recormon. He also led corporate and market development and strategy from inception to commercialization of the Elecsys system, which became one of the world’s most widely used immunodiagnostic platforms. Dr. Gill served on the Board of Directors of the Tuberculosis Alliance, The Djerassi Resident Artists Program and the International Advisory Board of INSEAD. Dr. Gill was also the founder of Dispatches, an in-depth written and photojournalism periodical focused on key global issues. Dr. Gill has an MBA from INSEAD and carried out his PhD with focus on developing humanized antibodies to treat cancer. This work was done at King’s College, London in collaboration with the LMB at Cambridge and Celltech.
Follow Simba Gill:
About Epiva, Evelo Biosciences, moksha8 Pharmaceuticals, TPG Growth: Evelo Biosciences is dedicated to improving the lives of patients globally through the development of monoclonal microbials.
Daniel Grau
President, Chief Executive Officer, and Director of Sojournix
Grau co-founded and has served as Chief Executive Officer and Director at Sojournix since 2016. An experienced biotech entrepreneur and operating executive, Mr. Grau led the deal to acquire SJX-653 and has driven the rapid growth and financing of the company from startup to clinical-stage pharmaceutical business. Prior to Sojournix, Mr. Grau served as President at Heptares Therapeutics (acquired 2015), Chief Executive Officer at Cortria (acquired 2010), and Chief Operating Officer at CombinatoRx (IPO 2005). Mr. Grau currently serves as an advisor to HotSpot Therapeutics and previously served as a member of the Product Advisory Board at Concert Pharmaceuticals and as an advisor to Nimbus Therapeutics. Earlier in his career, Mr. Grau worked with multi-national pharma companies as a management consultant focused on corporate and business franchise strategy, M&A, and new product launches. Mr. Grau earned his M.Phil., M.A., and M.A.R. degrees from Yale University, where he was awarded a Mellon Fellowship, the Day Graduate Prize, and a Bass Fellowship, and a B.A. with High Honors from Davidson College, where he held a Dana Honor Scholarship, a Montgomery Scholarship, and was elected to Phi Beta Kappa.
Follow Daniel Grau:
About Cortria Corporation, Heptares Therapeutics, Sojournix: Sojournix is a biotechnology company developing innovative medicines for women’s health and endocrine disorders.
Lanny Sun
Co-Founder & CEO of Silicon Therapeutics
Follow Lanny Sun:
About Silicon Therapeutics: Silicon Therapeutics is a fully integrated drug design, research, and development company.
Jonathan Montagu
President & Chief Executive Officer of HotSpot Therapeutics
Follow Jonathan Montagu:
About Atlas Venture, HotSpot Therapeutics: HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Nessan Bermingham
Founder, CEO & currently Exec Chair of Triplet Therapeutics
Nessan Bermingham is founder and CEO of Triplet Therapeutics, Inc. He is a serial biotech entrepreneur and investor who has founded several companies including Triplet, Korro Bio and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company,” taking the company from concept to IPO and large partnering deals with approximately 200 employees. He has nearly two decades of experience in Life Sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets. As a venture partner at Atlas Venture and managing partner at Omega Funds, he successfully invested in and managed multiple investments across the United States and Europe. Currently he is also a venture partner at Atlas Venture and is Chair of the Board of Directors of F-star and Akrevia Therapeutics. He served as Intellia’s President and CEO from inception until December 2017. Previously he was an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine. He is an avid mountain biker, snowboarder and trail runner. Nessan is co-founder and was previously chief executive officer of Intellia Therapeutics. He led Intellia from seed investment and incubation at Atlas Venture through its IPO and the advancement of its gene editing platform toward clinical development. He has over ten years of experience in life science investing across venture, secondary, and public markets. Previously, Nessan was a partner at Omega Funds and founder of Bio Equity Capital, a healthcare focused special situations firm. Nessan is also co-founder of Tal Medical.
Follow Nessan Bermingham:
About Korro Bio, Triplet Therapeutics: Triplet is developing transformative therapies that treat repeat expansion disorders at their source.
Jeff Albers
Chief Executive Officer of Blueprint Medicines
Jeff Albers is the chief executive officer of [Blueprint Medicines](https://www.crunchbase.com/organization/blueprint-medicines), a company engaged in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets. He was previously the president of Algeta. Prior to Algeta, he served at Genzyme, where he spent seven years in senior commercial and corporate development positions. Before joining Genzyme, he spent five years as an Attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo. He also has prior experience as a sales representative for Pfizer. Albers holds a bachelor’s degree in marketing from Indiana University and an MBA from Georgetown University.
Follow Jeff Albers:
About Blueprint Medicines: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
Mirza Cifric
Co-Founder & Chief Executive Officer of Veritas Genetics
Follow Mirza Cifric:
About Veritas Genetics, YPO: Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer.
Anna Villarreal
Founder & CEO of LifeStory Health Inc
Leading the first-ever discovery research into the clinical utility of menstrual blood, a recent Proof of Principle study resulted in findings of unique signatures specific to menstrual blood. On-going clinical studies aim to develop the diagnostic science further in order to support our preliminary pipeline. Anna’s resourceful leadership style and entrepreneurial experience has lead LifeStory Health, Inc. through remarkable discoveries and growth in a very short time when compared to most bioscience companies. She attributes this to her steadfast passion for and about Women’s Health. A strong advocate for women’s healthcare, Anna’s pioneering vision to map the menstrual blood proteome through a set of resolute, data-leading principles and an award winning scientific methodology has led to biomarker discovery based on precision medicine. Anna guest lectures for several graduate level programs at Northeastern University including data analytics, chemistry, regulatory affairs, and master’s in business administration. She teaches her own class in the Master’s of Biotechnology Program titled “Women’s Health: Driving Innovation and Cultural Change”. Her advocacy for women’s health continues on her podcast, “Setting the Pace”, in which she and her co-host highlight fellow female innovators.
Follow Anna Villarreal:
About CEOWORLD Magazine, LifeStory Health Inc, NEFC, The Doctor Weighs In: LifeStory Health is a biotech company committed to changing the women’s healthcare market through technology, innovation and vocalization.
Bill Haney
CEO & Co-founder of Dragonfly Therapeutics
Follow Bill Haney:
About Blu Homes, Dragonfly Therapeutics, Dragonfly Therapeutics, Skyhawk Therapeutics, Uncommon Productions: Dragonfly Therapeutics is a clinical-stage biotech developing novel immunotherapies that harness the innate immune system to treat disease.
Andrew Beck
Co-founder & CEO of PathAI
Andrew Beck earned a Bachelors of Arts in History from Brown University in 2002 and completed a Masters of Medical Science in Biostatistics and a Medical Degree from Brown Medical School in 2006. He completed his residency in Anatomic Pathology and clinical fellowship in Molecular Genetic Pathology from Stanford in 2010.He then joined the Advanced Residency Training at Stanford program and completed a PhD in Biomedical Informatics from Stanford University in 2013, working with Professor Daphne Koller. In 2011, he was appointed as an Assistant Professor in the Departmet of Pathology at Harvard Medical School and the Beth Israel Deaconess Medical Center. In 2016, he was promoted to Associate Professor. In 2016, Dr Beck co-founded PathAI, a company that develops artificial intelligence technology for pathology, where he serves as President and CEO.
Follow Andrew Beck:
About Beth Israel Deaconess Medical Center, PathAI: PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time.
Aoife Brennan
CEO of Synlogic
Aoife Brennan joined Synlogic in September 2016 as chief medical officer and is responsible for the oversight and direction of the company’s clinical development strategy and operations. Aoife previously spent six years at Biogen, where she was in roles of increasing responsibility and most recently served as vice president and head of the Rare Disease Innovation Unit, which included programs ranging from pre-clinical to commercial. She has also led programs across multiple therapeutic areas including the late phase development of nusinersen for spinal muscular atrophy and ALPROLIX™ and ELOCTATE™, treatments for Hemophilia B and Hemophilia A. Prior to joining Biogen, she was director of clinical development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes. Aoife holds a medical degree from Trinity College in Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology and metabolism. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.
Follow Aoife Brennan:
About Synlogic: Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.
Nick Davis
Founder, President, and Chief Executive Officer of Theonys
Nick Davis is the Founder, President & Chief Executive Officer of Theonys — a therapeutics company developing new small-molecule medicines to selectively stop the translation of disease-causing proteins in cancer, chronic inflammation and other serious human diseases.
Follow Nick Davis:
About Massachusetts Institute of Technology, Theonys: Theonys is harnessing the power of tRNA to pioneer an entirely new class of genomic medicines.
Nello Mainolfi
Founder, President & CEO of Kymera Therapeutics
Nello Mainolfi is the Founder, President, and Chief Executive Officer at Kymera Therapeutics.
Follow Nello Mainolfi:
About Kymera Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Greg Verdine
Co-Founder, President & CEO, CSO of LifeMine Therapeutics
Greg Verdine is the Founder of Gloucester Marine Genomics Institute & he attended Massachusetts Institute of Technology in 1986.
Follow Greg Verdine:
About FogPharma, Gloucester Marine Genomics Institute, Harvard Medical School, Harvard University, LifeMine Therapeutics, Massachusetts Institute of Technology, Wave Life Sciences: Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology.
Chris Adams
CEO of Andarix Pharmaceuticals
Adams previously founded and served as CEO of several companies including Walleye Technologies, Diopter Corporation, and Mosaic Technologies. At all three organizations, Mr. Adams was instrumental in raising venture capital, forming scientific and business advisory boards, recruiting and hiring key employees, and negotiating key corporate agreements and research collaborations. Diopter invented and developed a biological contact lens to treat corneal scarring. The technology was successfully sold and has been used on over 25,000 patients to help maintain a healthy cornea. He was also responsible for the successful commercialization of several other products including the “see through solid surfaces” Millimeter Wave Camera, a product which won Time Magazines prestigious Top 10 Innovations of 2009 award. Mr. Adams performed graduate work in molecular immunology at the University of Massachusetts and was on the research staff at the Massa chusetts Institute of Technology Human Genome Center. He received a BA from Assumption College and is the inventor on 18 patents.
Follow Chris Adams:
About Andarix Pharmaceuticals, Ceeable: Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond.
Kfir Schreiber
Co-Founder & CEO of DeepCure
Kfir Schreiber is the CEO and Co-Founder of at DeepCure.
Follow Kfir Schreiber:
About DeepCure: DeepCuris builds an AI engine for small-molecule drug discovery.
Pieter Muntendam
President and CEO of SQ Innovation
Follow Pieter Muntendam:
About G3 Pharmaceuticals, SQ Innovation: SQ Innovation is a biopharmaceutical company that develops and commercializes pharmaceutical products.
George Scangos
CEO of Vir Biotechnology
George A. Scangos, Ph.D., is the chief executive officer and a member of the Board of Directors of VIR. Previously, he was the chief executive officer and a member of the board of directors of Biogen since July 2010. From 1996 to July 2010, Dr. Scangos served as the president and chief executive officer of Exelixis, Inc., a drug discovery and development company, where he continues to serve on the board. From 1993 to 1996, Dr. Scangos served as president of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products. Before joining Bayer in 1987, Dr. Scangos was a professor of biology at Johns Hopkins University, where he is still an adjunct professor. Dr. Scangos served as non-executive chairman of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 to July 2010 and was a director of the company from 2003 to July 2010. He currently serves on the Boards of Directors of Agilent, Exelixis, and Decibel Therapeutics.
Follow George Scangos:
About Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases.
Brian Stuglik
CEO of Verastem Oncology
Brian Stuglik was appointed to Chief Executive Officer (CEO) of Verastem Oncology in July, 2019. Mr. Stuglik is a global leader in the oncology pharmaceutical sector with over 3 decades of experience in US and International pharmaceutical development, product strategy, commercialization and business development. He successfully developed, acquired and launched several multi-billion dollar oncology brands across multiple tumor types and therapeutic approaches. Brian founded Proventus Health Solutions, a company specializing in helping oncology biotech companies create greater value by integrating development and commercial considerations into a unified approach. Currently, he serves as a member of the board of directors for Verastem Oncology (VSTM) and Oncopeptides AB (ONCO).
Follow Brian Stuglik:
About Verastem Oncology: Verastem is a biopharmaceutical company that focuses on discovering and developing novel drugs that selectively target cancer stem cells.
Michael T. Heffernan
President , CEO & Chairman of the Board of Collegium Pharmaceutical
Michael Heffernan has 25 years of experience in the pharmaceutical and related healthcare industries. He is currently Co-Founder, President, CEO of Collegium Pharmaceutical. Collegium is specialty pharmaceutical company focused on the development of pharmaceutical products for the treatment of chronic pain. He was also previously the founder, President and CEO of Onset Therapeutics, a dermatology focused company that develops and commercializes products for the treatment of skin related illnesses and was responsible for the spin-off of this business to create PreCision Dermatology. Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that he successfully sold. He also served as President and CEO of PhyMatrix, a public $400 million integrated healthcare services company where he was hired to restructure the company. Michael started his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been a member of the Board of Directors, Advisor and Angel Investor in a number of healthcare companies. He is currently a member of the Board of Directors of TyRx, a venture backed medical device company, Cornerstone Therapeutics (NASDAQ:CRTX), a specialty pharmaceutical company and PreCision Dermatology. Michael earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.
Follow Michael T. Heffernan:
About AvengeBio, Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Joseph Ciaffoni
President and Chief Executive Officer of Collegium Pharmaceutical
Joe Ciaffoni was appointed President and Chief Executive Officer of Collegium Pharmaceutical in July 2018. Joe Ciaffoni joined Collegium Pharmaceutical in May 2017 as Executive Vice President and Chief Operating Officer. Prior to joining Collegium, he served as President, U.S. Branded Pharmaceuticals of Endo International plc. Before that, Joe Ciaffoni held various positions of increasing responsibility at Biogen, including Senior Vice President, Global Specialty Medicines Group, Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen, he was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals. Joe Ciaffoni also previously served as Vice President, Sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Joe Ciaffoni received a B.A. in Communications and an M.B.A. from Rutgers.
Follow Joseph Ciaffoni:
About Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Amarpreet Sawhney
CEO of Instylla
Amar is the President and CEO of Octux, Inc. a company focused on unmet needs in ophthalmic surgical wound closure and drug delivery. Previously, he was Founder and CEO of Confluent Surgical (acquired by Covidien), a biosurgery company. He was Chairman of marketRx (acquired by Cognizant), a provider of pharmaceutical marketing and sales analytics and intelligence. Before Confluent, Amar was the technology founder of Focal, Inc. (acquired by Genzyme). Amar’s innovations are the subject of almost 100 issued and pending patents. He is a board member of Soteira, Square One and TiE Boston. He is a board member and founder of Access Closure, Octux, Augmenix, and Incept LLC. Amar volunteers his time with entrepreneurial organizations including TiE Boston, MassMedic, and the E&Y Entrepreneur of the Year program. Amar and Confluent have been recognized with awards including MassMedic best startup company award, Frost and Sullivan Product innovation award, MIT Global Indus Technovators Award, E&Y regional entrepreneur of the year award, Mass High Tech All Star award, and University of Texas Outstanding Young Engineering Graduate award. Amar holds a Ph.D. and M.S. in Chemical Engineering from the University of Texas at Austin and a B.Tech. in Chemical Engineering from the Indian Institute of Technology, New Delhi.
Follow Amarpreet Sawhney:
About Incept, Instylla, SpaceOAR: Instylla’s focus is to leverage hydrogel technology .
Liang Schweizer
Co-founder, President and CEO of HiFiBiO
Liang Schweizer is the Co-founder, President and CEO of HiFiBiO Therapeutics. Previously, she co-founded Harbour Biomed and served as its CSO, successfully transforming a technology platform company to an antibody drug discovery enterprise. Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi, advancing Sanofi’s Asia-Pacific oncology pipeline as well as contributing to global oncology programs from preclinical to clinical efforts. Before joining Sanofi, Liang Schweizer was a director at Bristol-Myers Squibb Company, heading a group of scientists at Leads Discovery and Optimization (LDO), overseeing 60+ in vitro pharmacology projects across different therapeutic areas. Under her leadership, the team made significant contributions to 4 marketed drugs and impacted over 20 clinical candidates. She is also a co-inventor of multiple BMS Immunoncology (IO) clinical candidates. Liang Schweizer graduated from the University of Science and Technology of China (USTC) majoring in Biology. She received her Master’s degree in Microbial Engineering at the University of Minnesota with minor in Chemical Engineering. Liang earned her Ph.D. in Molecular Biology from the University in Zurich, Switzerland. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC), New York.
Follow Liang Schweizer:
About HiFiBiO: HiFiBiO provides proprietary single cell technologies for applications in drug and biomarker discovery and development.
Michel Vounatsos
Chief Executive Officer of Biogen Idec
Michel Vounatsos is Executive Vice President and Chief Commercial Officer at Biogen. Michel brings extensive global biopharmaceutical experience and a track record of innovative stakeholder engagement to his leadership of the company’s commercial organization. Michel joined Biogen in 2016 after a 20 career at Merck, where he most recently served as President, Primary Care Business Line and Merck Customer Centricity. In this role, he led Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups, and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payers and retailers and the world’s largest governments. Michel previously held leadership positions across Europe and in China for Merck. Earlier in his career, Michel held management positions at Ciba-Geigy. Michel received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.
Follow Michel Vounatsos:
About Biogen Idec: Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Bicheng Han
CEO of BrainCo
Bicheng Han is the founder and CEO of Brainco. He founded the company in 2014. A year after, Han founded BrainRobotics. Han earned his PhD from Harvard University, Center of Brain Science. He is a brain science, medical device expert.
Follow Bicheng Han:
About BrainCo, BrainRobotics, Harvard University: BrainCo strives to apply brain machine interface (BMI) and neurofeedback training to optimize the potential of the human brain.
Tony Coles
Chairman and CEO of Yumanity Therapeutics
Anthony Coles was named Chairman and Chief Executive Officer of Yumanity Therapeutics, LLC, a company focused on transforming drug discovery for neurodegenerative diseases, in October 2014. Prior to this, from October 2013, Anthony Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately-held company. Anthony Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company (“Onyx”), from 2012 until 2013, having served as its President, Chief Executive Officer and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer and a member of the board of directors of NPS Pharmaceuticals, Inc., a public biopharmaceutical company (“NPS”). Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings and Campus Crest Communities, Inc. Anthony Coles has been a director of the Company since April 2014. He is a member of the Compensation Committee and the Finance Committee.
Follow Tony Coles:
About Yumanity Therapeutics: Yumanity Therapeutics is a biotechnology company that transforms drug discovery for diseases caused by protein misfolding.
Stephane Bancel
President and Founding CEO of Moderna Therapeutics
Stephane joined Flagship Ventures in 2013 and focuses on providing strategic counsel and support to portfolio companies. He is President and Founding Chief Executive Officer of Moderna Therapeutics, a Flagship VentureLabs – founded company. He is also executive chairman of the board for portfolio company BG Medicine, Inc. Stephane was previously CEO of bioMerieux, a world leader in the diagnostics industry. During his five years leading the company, he accelerated the company’s sales growth rate, enhanced its position as a global leader in clinical microbiology and re-accelerated its immunoassay franchise by focusing on high medical value biomarkers. During that time, the company’s market capitalization nearly doubled despite the financial crisis. Prior to his time at bioMerieux, Stephane was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis. He holds a Master of Engineering from Ecole Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School. Stéphane was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for Investor Relations in France in 2009 and was ranked #1 CEO in the Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study.
Follow Stephane Bancel:
About Flagship Pioneering, Moderna Therapeutics, Qiagen: Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Kurt Graves
President & CEO of Intarcia Therapeutics
Follow Kurt Graves:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Jonathan Solomon
CEO of BIOMx
Jonathan Solomon is the CEO of BiomX.
Follow Jonathan Solomon:
About BIOMx: BIOMx is a microbiome therapeutics company developing synbio phage therapies to eradicate harmful bacteria in chronic diseases.
Jen Nwankwo
Founder, CEO of 1910 Genetics
Jen Nwankwo is the Founder and CEO at 1910 Genetics.
Follow Jen Nwankwo:
About 1910 Genetics: 1910 Genetics is a biotechnology company integrating AI, computation, and biological automation to improve drug development.
Jon Heimer
CEO of Olink
As President and CEO of Olink Proteomics the vision and goal is to facilitate and implement Precision Medicine via discovery and development of validated protein targets to identify smaller protein signatures for e.g. stratification and prediction and advance them in to clinical decision making. Jon is an entrepreneur and has spent the last 25 years in various biotech start-up companies, developing and commercializing medical devices and biotech drugs. He studied economy at the Uppsala University and has an MBA from IHM Business school in Stockholm. Jon was part of a small team that started Swedens latest most successful biotech which grew to 800 people around the world, market leader in its segment, went public and eventually sold to Galderma. Prior to joining Olink Proteomics as President and CEO he ran a small orphan drug company developing two drugs into late stage clinical trials through the FDA with novel treatments for hyperoxaluria.
Follow Jon Heimer:
About Olink: Olink develops ground-breaking technologies for biomolecular analysis.
Alec Nielsen
Founder & CEO of Asimov
Alec Nielsen is the Founder & CEO at Asimov.
Follow Alec Nielsen:
About Asimov: Asimov builds tools to program living cells.
Ronald Renaud
Chief Executive Officer of Translate Bio
Ronald Renaud has served as the President and chief executive officer of Idenix Pharmaceuticals, Inc. since October 2010. Prior to this, Ronald Renaud has served as the chief financial officer of Idenix Pharmaceuticals, Inc. since June 2007 and additionally as Chief Business Officer since June 2010. Ronald Renaud brings a unique mix of skills to this role with his finance experience at public biotechnology companies and on Wall Street, as well as his science background. Prior to joining Idenix, Ronald Renaud served as chief financial officer of Keryx Biopharmaceuticals. In this role he was responsible for the strategic planning and development of the finance function to support the company’s growth and its late-stage product candidate development. Prior to his position at Keryx, he spent several years as a senior biotechnology equity analyst for leading investment banks including Bear Stearns, Schwab SoundView and JP Morgan. Additional industry experience includes Mr. Renaud’s more than five years at Amgen Inc., where he held positions in clinical research, investor relations and finance. Ronald Renaud holds a Masters in Business Administration from the Marshall School of Business at the University of Southern California and a Bachelor of Arts from St. Anselm College in Manchester, NH.
Follow Ronald Renaud:
About Translate Bio: Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Adam Behrens
CEO of Mori
Adam Behrens is the Co-Founder and Chief Executive Officer at Cambridge Crops.
Follow Adam Behrens:
About Mori: Mori is a developer of a protective silk coating product that extends the shelf life of perishable foods.
Kuldeep Singh Rajput
Founder & CEO of Biofourmis
Kuldeep Singh Rajput is the CEO and Founder of Biofourmis, a fast-growing digital health company filled with committed, passionate people who care about augmenting personalized care and empowering people with complex chronic conditions to live better and healthier lives. Biofourmis is pioneering an entirely new category of digital health, by developing clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Recognized as the “Forbes 30 Under 30”, Kuldeep has demonstrated strong leadership experience with building teams, developing talents, and successfully growing, and managing strategic partnerships with global pharmaceutical manufacturers, health systems and Payers. Under his leadership, Biofourmis has raised over US$45 Million in venture capital from leading Venture Capital firms including Sequoia Capital, MassMutual Ventures, Singapore Govt-linked EDBI, Aviva plc, and Mayo Clinic Ventures. He uses his background and experience in biomedical engineering and data from the Massachusetts Institute of Technology (MIT) to unfold his vision of “Predicting and Preventing Serious Medical Events using AI”. During his Ph.D. studies at the National University of Singapore (NUS), he built bioelectronic implants, which aim to control biological processes and treat diseases by modulating electric impulses. He believes in giving back and is part of the Milken Institute Young Leaders Circle (YLC), supporting the mission of providing people access to education and healthcare for stable economic growth. Kuldeep has been featured in major publications and has been a keynote speaker at numerous prestigious conferences like TED. Specialties: Entrepreneur, Fund Raising, Building Companies, Digital Therapeutics, Licensing, and Deal Structure, Healthcare Strategy, Digital Healthcare, Wearable Biosensors, Pharmaceuticals
Follow Kuldeep Singh Rajput:
About Biofourmis: Biofourmis is a biotechnology company that augments personalized care and therapies using digital therapeutics.
Paul Holzer
CEO and Co-Founder of XenoTherapeutics
Paul Holzer serves as CEO and co-founder of XenoTherapeutics. He is a scientist, engineer, and entrepreneur with over fifteen years of experience in various leadership and team management roles, and most recently in the fields of scientific research and new venture formation. Prior to founding XenoTherapeutics, Paul served as an Officer in the United States Navy SEAL Teams, with four decorated combat deployments to theatres such as Iraq, Afghanistan, and other undisclosed locations. He left the Navy in 2013 as a Lieutenant Commander (0-4) in the USNR.
Follow Paul Holzer:
About XenoTherapeutics: XenoTherapeutics is a clinical-stage cell and gene therapy company engineering immune-compatible cells, tissues, and organs.
Chen Schor
Co-Founder, President & CEO of resTORbio
Schor is a global healthcare industry leader with vast experience in pharmaceuticals, biotechnology, medical devices, business development and private equity. Schor has supported and helped build multiple healthcare companies and led multiple licensing, partnerships and M&A transactions with total value exceeding $8 billion with companies such as GSK, Amgen, Pfizer, Bayer, Teva and EMD-Serono. Prior to joining Novalere, Schor was VP Global Business Development with Teva Pharmaceuticals and had leadership roles at several emerging pharmaceutical and biotechnology companies. Schor was also a Partner at Yozma venture capital where he led the foundation and growth of multiple companies from inception to significant commercial success. Schor holds a Master in Business Administration, a B.A. in Biology, a B.A. in Economics, and is also a Certified Public Accountant (CPA).
Follow Chen Schor:
About Novalere FP, Predix Pharmaceuticals, resTORbio, Synta Pharmaceuticals: resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics.
Jean Sommadossi
Founder & Chief Executive Officer of Idenix Pharmaceuticals
Jean-Pierre Sommadossi is a veteran in the field of biotechnology. Jean Sommadossi was the Principal Founder of Idenix Pharmaceuticals, Inc (NASDAQ: IDIX) and a co-Founder of Pharmasset, Inc (NASDAQ: VRUS), and served as Chairman and Chief Executive Officer of Idenix Pharmaceuticals from November 2000 to November 2010. From 1998 to November 2000, Jean Sommadossi has served as Chairman of the Board of Directors and then as Executive President and Chief Scientific Officer. Under his leadership, Idenix has raised more than $450 million in private and public equity financings and entered into multiple strategic partnerships, including those with Sumitomo and GlaxoSmithKline (GSK) as well as a landmark biotechpharma transaction with Novartis Pharma AG in 2003. Prior to founding Idenix, Jean Sommadossi was on the Faculty of The University of Alabama at Birmingham School of Medicine since March 1985. He has served as a Professor of Pharmacology, Toxicology and Clinical Pharmacology as well as an Associate Director of both the Center for AIDS Research and The Liver Center from June 1992 to November 2000. Jean Sommadossi has authored over 180 peer-reviewed publications and holds more than 50 US patents related to the treatment of Cancer and Infectious Diseases. Jean Sommadossi has earned his Pharm.D. and Ph.D. in Pharmacology degrees from the University of Marseilles in France. He was a postdoctoral Fogarty Fellow at the National Cancer Institute and the Medical College of Virginia and a recipient of a Faculty Award from The American Cancer Society. Jean Sommadossi currently is a Senior Advisor to PureTech Ventures. Jean Sommadossi was recently named to the Therapeutics Advisory Council of Harvard Medical School.
Follow Jean Sommadossi:
About Atea Pharmaceuticals, Idenix Pharmaceuticals: Idenix Pharmaceuticals is focused on the discovery and development of drugs for the treatment of human viral diseases.
Hugh O’Dowd
President & CEO of Neon Therapeutics
Neon Therapeutics’ chief executive officer, Hugh O’Dowd, joined the company in 2016, bringing more than 20 years of expertise in pharmaceutical leadership and moving important oncology therapies from clinical development through commercialization. Hugh joined Neon Therapeutics from Novartis Oncology, where he spent more than 20 years in a variety of leadership roles, including chief commercial officer and head of global strategy. In this role, he was responsible for global commercialization for the oncology portfolio, including global brand leadership, health economics and pricing, early phase commercial development, strategic capabilities, business development, and licensing and global sales excellence. Hugh began his career in pharmaceuticals in 1992 at Glaxo in sales, and moved to Novartis in 1996. Following a career of increasing levels of responsibility in sales and marketing, he took a leading role in the commercialization of Gleevec, and assumed country- and region-level commercial leadership roles before overseeing the entirety of Novartis Oncology commercialization and strategy in 2011. Since 2015, Hugh was country president and general manager of Novartis in the United Kingdom and Ireland. Hugh holds a B.A. from Loyola University Chicago, and an MBA from the Kellstadt Graduate School of Business at DePaul University Chicago.
Follow Hugh O’Dowd:
About Neon Therapeutics: NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
Robert Coffin
Founder and CEO of Replimune Group
Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in the US. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.
Follow Robert Coffin:
About Replimune Group: Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Jeff Valk
Chief Executive Officer of Admetsys
Follow Jeff Valk:
About Admetsys: For people at diabetic risk, glucose control is at its most crucial while in hospital or surgery.
Daphne Zohar
Founder, CEO of PureTech Health
Daphne Zohar is the founder and managing partner of PureTech, a technology development company tackling tomorrow’s biggest healthcare challenges. Ms. Zohar was recognized by Fierce Biotech as one of the “Top 10 Women in Biotech,” BioWorld as one of 28 leaders predicted to be the “movers and shakers” of the biotechnology industry over the next twenty years, and by the Boston Globe as one of the “Top 15 Innovators.” A successful entrepreneur, Ms. Zohar created PureTech and assembled a leading team to help implement her vision for the firm. She sits on the Boards of Directors of PureTech, Enlight (a cross disciplinary consortium of leading healthcare and pharma companies), Follica Inc., Akili Interactive Labs, Vedanta Bioscience, Mandara Sciences, Karuna Pharmaceuticals, and Tal Medical. She also sits on the Technology Development Fund Advisory Board at Children’s Hospital Boston and is an Editorial Advisor to Xconomy, a national technology news blog.
Follow Daphne Zohar:
About PureTech Health: PureTech Health is a bio pharma company and pushes the boundaries of medicine and changing and converging healthcare ecosystem.
Shawn Marcell
Co-Founder, President & CEO of Torus Biosystems
Follow Shawn Marcell:
About Torus Biosystems: Torus Biosystems is a biotech startup that delivers molecular diagnostics for infectious diseases.
Jose Almeida
President and CEO of Baxter International
Jose Almeida is chairman and chief executive officer of Baxter International Inc. Prior to joining Baxter in October 2015, Almeida served as chairman, president and chief executive officer of Covidien plc from 2012 through 2015 and was named a director of the company in 2011. Almeida previously served as president of Covidien’s Medical Devices organization, where he oversaw several businesses accounting for approximately two-thirds of the company’s total annual revenues and approximately three-quarters of its operating profit. Almeida also served in several leadership roles at Covidien’s predecessor, Tyco Healthcare, including president of its worldwide medical device business and vice president of worldwide manufacturing. In addition to Covidien and Tyco, Almeida held leadership positions at Wilson Greatbatch Technologies, Inc., American Home Products’ Acufex Microsurgical division, and Johnson & Johnson’s Professional Products division. He began his career as a management consultant at Andersen Consulting (Accenture). Almeida served as chairman of the board of directors of Advamed from 2014 to 2015 and has been an active member of the AdvaMed board since 2005 and its executive committee since 2010. He also serves on the Board of Trustees of Partners in Health. A native of Brazil, Almeida received a bachelor’s of science degree in mechanical engineering from Escola de Engenharia Mauá in São Paulo.
Follow Jose Almeida:
About Baxter International, The Carlyle Group: Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people.
Geoff MacKay
Founder, President & CEO of Avrobio
Geoff is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is the former CEO of Organogenesis Inc., the world’s leading cell therapy company. During his tenure at the helm, the company treated 1 million patients with living cell therapies, received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and led the field of regenerative medicine. Geoff is also the founding CEO of eGenesis, a biotech dedicated to applying CRISPR Cas-9 gene editing to xenotransplantation. Earlier in his career, Geoff spent 11 years at Novartis in senior leadership positions within the global transplantation and immunology franchise. Geoff sits on the boards of Talaris Therapeutics and Satellos Bioscience. Past activities include chairman of the board of MassBio, chairman of the board of the Alliance of Regenerative Medicine, and a member of the advisory council to the Health Policy Commission for Massachusetts.
Follow Geoff MacKay:
About Atlas Venture, Avrobio: Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
David Hallal
CEO, Chair, & Co-Founder of ElevateBio
David Hallal, Chairman and CEO of ElevateBio, is a 30-year veteran in the biopharmaceutical industry, with expertise in early-stage company building as well as operating large multinational biotech companies. He also is Chairman and CEO of AlloVir, an ElevateBio portfolio company. Previously, David spent more than a decade at Alexion Pharmaceuticals as Chief Executive Officer, Chief Operating Officer, and Chief Commercial Officer and played a central role in transforming the company from the pre-commercial stage in 2006 to greater than $3 billion in annual revenues by 2016. As the Chief Executive Officer of Alexion, David transitioned the company from a single-product to a multi-product enterprise. This included the US, EU, and Japan approval and the highly successful launch of Strensiq® and the rapid advancement of Alexion’s highest value pipeline candidate, Ultomiris, from a preclinical stage to registration trials in multiple diseases in just 18 months. Prior to his appointment as CEO, David served as Alexion’s Chief Commercial Officer and then Chief Operating Officer, where he built the company’s commercial infrastructure and a 50-country operating platform which launched Soliris® for two ultra-rare diseases, Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome, resulting in the most successful commercialization of an ultra-orphan drug in the biotechnology industry. Prior to Alexion, David held commercial leadership positions at biopharmaceutical companies where he launched and expanded the adoption of numerous first-in-class and blockbuster products in hematology, oncology, nephrology, immunology and ophthalmology, as the Vice President of Sales at OSI Eyetech and at Biogen where he led the immunology sales team. Prior to Biogen, David has also held various leadership roles at Amgen focused on the major oncology and hematology products Epogen®, Neupogen®, Neulasta® and Aranesp®. David serves as the Chairman of Scholar Rock (Nasdaq: SRRK), Chairman of iTeos Therapeutics, and is an independent director of Seer Biosciences. David is also an executive partner at MPM Capital. He holds a BA in psychology from the University of New Hampshire.
Follow David Hallal:
About Basecamp Bio, ElevateBio, Enobia Pharma: ElevateBio is a biotechnology company that specializes in cell and gene-based therapies.
Elisabet de los Pinos
Founder and CEO of Aura Biosciences
Follow Elisabet de los Pinos:
About Aura Biosciences: Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Robin Smith
Founder & CEO of ORIG3N
Robin Y Smith is the Founder and CEO of ORIG3N, a biotechnology company developing a breakthrough disease-modeling platform targeting rare genetically inherited diseases and DNA testing solutions for Health and Wellness. Visit: www.orig3n.com
Follow Robin Smith:
About ORIG3N: ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Jeffrey D. Wager
Co-Founder, Chairman & CEO of EnBiotix
Follow Jeffrey D. Wager:
About EnBiotix, Proterris: EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
Romesh Subramanian
CEO and Founder of Dyne Therapeutics
Romesh Subramanian is the CEO and founder of Dyne Therapeutics.
Follow Romesh Subramanian:
About Dyne Therapeutics: Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Murali Aravamudan
Founder & Chief Executive Officer of Qrativ
Murali Aravamudan is Co-Founder and CEO of nference. Aravamudan was originally a researcher at Bell Labs, and helped build the first VoIP softswitch, which was deployed at Level3 and other companies. During the last boom, his first company, Winphoria, built a push-to-talk technology that competed with [Nextel](http://www.crunchbase.com/organization/nextel)’s. It was adopted by [Sprint](http://www.crunchbase.com/organization/sprint-nextel) and Verizon. The company raised $52 million, and was sold to [Motorola](http://www.crunchbase.com/organization/motorola) for $190 million in 2003.
Follow Murali Aravamudan:
About Anumana, nference, Qrativ: Qrativ is a developer of a drug purposing platform designed to reinvent the way treatments for diseases with unmet medical.
Earl Collier
CEO of 480 Biomedical
Earl M. (Duke) Collier, Jr. is Executive Chairman of Arsenal Medical and serves as CEO of 480 Biomedical. For many years, Collier was executive vice president at Genzyme Corporation. He has also served as president of Vitas Healthcare, a partner at the Washington, DC-based law firm of Hogan and Hartson (now Hogan Lovells) and as Deputy Administrator of the Health Care Finance Administration (now CMS) in the Department of Health and Human Services. Earl Collier sits on the boards of 480 Biomedical, Arsenal Medical, Capricor, Transmedics and Newton-Wellesley Hospital. He earned a Bachelor of Arts at Yale University and received a law degree from the University of Virginia Law School.
Follow Earl Collier:
About 480 Biomedical: 480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.
Keith M. Gottesdiener
Chief Executive Officer of Motus Therapeutics
Keith Gottesdiener is the President & CEO at Prime Medicine, Inc..
Follow Keith M. Gottesdiener:
About Motus Therapeutics, Prime Medicine: Motus Therapeutics is a biotechnology company developing peptide therapeutics for the treatment of metabolic diseases.
John Maraganore
CEO of Alnylam Pharmaceuticals
Chief Executive Officer & Director at Alnylam Pharmaceuticals.
Follow John Maraganore:
About Alnylam Pharmaceuticals, Alnylam Pharmaceuticals, Third Rock Ventures: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
John Leonard
President , Chief Executive Officer & Member Board of Directors of Intellia Therapeutics
After a 30-year career in pharmaceutical R&D, John Leonard retired from his position as Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality. John is among the leading R&D executives who have led breakthrough medicines through their discovery, development and launch into blockbuster drugs. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide, and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research. In addition to serving on the Board of Directors of Intellia, John serves on the Board of Directors of QuintilesIMS (NYSE:Q) and Chimerix (Nasdaq:CMRX). He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in Internal Medicine at Stanford University School of Medicine followed by a fellowship at the National Institutes of Health.
Follow John Leonard:
About Intellia Therapeutics: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
David Berry
Founder and CEO of Valo Health
David Berry, M.D., PhD., is an American inventor, entrepreneur, venture capitalist and CEO. Berry has co-founded and helped build over 10 companies in life sciences, technology, and sustainability. In 2007, he was named as the Innovator of the Year from the MIT Technology Review TR35 list of one of the top 35 innovators in the world under the age of 35. He was selected as a 2014 Young Global Leader by the World Economic Forum. In 2007, Berry founded Joule Unlimited, which is developing Solar Fuels—drop-in fuels produced directly from the sun. Berry served as President and CEO of the company through April 2009, and currently serves on the Board of Directors. Joule is pioneering solar fuels through a new technology that coverts sunlight, carbon dioxide, and salt water into drop-in fuels for prices as low as $20. In March 2010 and again in March 2011, Joule was named by Technology Review as one of the 50 Most Innovative Companies. Joule was named as one of the 10 most important emerging technologies in 2011. Joule’s unique and innovative approach to fuels led to its being named a Technology Pioneer by the World Economic Forum in 2012 and to its receiving the Silver Medal in the 2011 Wall Street Journal Technology Innovation Awards. Joule’s technology has now been successfully scaled to a demonstration facility, and the company has announced a commercial partnership with Audi. Berry has been recognized multiple times as one of the top people in bioenergy by Biofuels Digest. In 2009, Berry founded Pronutria, which is pioneering a new approach to unlock the vast untapped therapeutic potential of proteins in the diet. Berry served as President and CEO through March 2012. Pronutria has built a proprietary database that contains over 1 billion food proteins, and leverages 40 years of clinical data that validates the pharmacological activity of particular amino acid combinations to identify proteins that, when delivered orally, act as prodrugs. The protein delivery form allows for of important drug-like properties including pharmacokinetic control and improvement of physiochemical features. Pronutria has advanced two of its ProNutrein™ into clinical trials. In 2011, Berry founded Seres Health, a company that develops a new class of therapeutics based on insights into the biology of the human microbiome. Seres Health has developed a new approach to functionally assess the changes of the microbiome associated with disease, and identifies a consortia of organisms that can catalyze a shift to health. Seres has advanced is lead into the clinic for recurrent C. difficile. In 2005, Berry co-founded LS9, with Chris Somerville, Jay Keasling, and George M. Church, which uses synthetic biology to engineer microorganisms to covert sustainable, plant-based materials into low-carbon fuels and chemicals. LS9 has successfully built on technologies he invented with other co-founders to produce a scalable platform for renewable fules and chemicals. This technology was successfully scaled to a fully operational 135,000L facility in Okeechobee, Florida. The impact and importance of LS9’s technology led to its being named a Technology Pioneer by the World Economic Forum in 2008 and its being awarded the Presidential Green Chemistry Challenge Award in 2010, the U.S. Environmental Protection Agency’s highest environmental honor. LS9 was acquired by Renewable Energy Group in 2014. Berry joined Flagship Ventures, a Cambridge, Massachusetts based venture capital firm that invests in and founds companies in healthcare and sustainability, in 2005 where he is a Partner. Berry has been described “a rising star of the Boston-area venture capital scene,” and “one of the most brilliant thinkers.” Berry serves on the Board of Directors of Joule Unlimited, Seres Health, Pronutria, Eleven Biotherapeutics (NASDAQ: EBIO), and Symbiota. Berry has been an author of 14 scientific papers and over 60 patent applications.
Follow David Berry:
About Axcella, Evelo Biosciences, Flagship Pioneering, Hackley School, Indigo, Joule Unlimited Technologies, Omega Therapeutics, Seres Therapeutics, Seres Therapeutics, Valo Health: Valo Health uses human-centric data and machine learning-anchored computation to transform the drug discovery and development process.
Nagesh K. Mahanthappa
CEO of Scholar Rock
Nagesh Mahanthappa is a biotechnology entrepreneur with over 20 years of industry experience in roles spanning discovery research through early clinical development, as well as operations and strategy. Prior to Scholar Rock, Nagesh Mahanthappa was a founding employee and VP, Corporate Development at Avila Therapeutics, Inc. (acquired by Celgene Corporation in 2012). Avila discovered and developed novel covalent drugs for the treatment of cancer, autoimmune, and viral diseases. He was previously a founding employee of Alnylam Pharmaceuticals, the first biotech established to discover RNA interference therapeutics and rose to VP, Scientific & Strategic Development. Earlier professional roles include business development at Vertex Pharmaceuticals, and discovery research at Ontogeny (now Curis, Inc.) and Cambridge NeuroScience. He was also a founder of TwistDx, a DNA diagnostics company acquired by Inverness Medical Innovations (now Alere, Inc.) in 2010. Nagesh Mahanthappa received his Ph.D. in Neurobiology from the California Institute of Technology, and post-doctoral training at the E.K. Shriver Center for Mental Retardation (then affiliated with Massachusetts General Hospital) and Harvard Medical School. He received his MBA from the F.W. Olin Graduate School of Management at Babson College.
Follow Nagesh K. Mahanthappa:
About Scholar Rock: Scholar Rock is discovering and developing a new class of biologic therapies.
Tillman Gerngross
Co-Founder and CEO of Adagio Therapeutics
Tillman Gerngross Co-Founded Adimab, LLC. in 2007 and serves as its Chief Executive Officer. Tillman Gergross is Founder of Arsanis Inc. and serves as its Chairman of the Board. Tillman Gergross Co-Founded Kreogene. He is a Co-Founder and Chairman of Alector LLC and Arsanis, Inc. He Co-Founded Avitide, Inc and serves as its Chairman of the Board.
Follow Tillman Gerngross:
About Adagio Therapeutics, Adimab, Arsanis, SV Health Investors: Adagio Therapeutics offers research and development of therapeutic pharmaceuticals related to COVID-19.
Richard Labaudinière
CEO of Protego Biopharma
Richard Labaudiniere currently works as the Chief Executive Officer for Protego Biopharma.
Follow Richard Labaudinière:
About Protego Biopharma: Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy.
Peter M. Hecht
Co-Founder & CEO of Cyclerion Therapeutics
Peter Hecht has served as Ironwood’s CEO and a director since co‐founding the company in 1998. He started Ironwood because he was attracted to “the idea of working with a team of people who challenge, inspire and humble me,” and building an enduring organization dedicated to creating important medicines. Under his leadership, Ironwood has grown from nine Ph.D. scientists to a fully‐integrated research, development and commercial organization. Prior to founding Ironwood, Peter was a research fellow at Whitehead Institute for Biomedical Research, an affiliate of Massachusetts Institute of Technology (MIT). He earned his Ph.D. in molecular biology from the University of California at Berkeley as well as a B.S. in mathematics and an M.S. in biology from Stanford University.
Follow Peter M. Hecht:
About Cyclerion Therapeutics: Cyclerion Therapeutics is a clinical-stage biopharmaceutical company.
Roman Fleck
CEO of Janpix
Roman currently serves as the CEO of Janpix, an oncology-focused start-up. He was formerly an advisor to Index Ventures and, before that, a Principal at Index, where among others he invested in and represented the firm on the boards of GlycoVaxyn (sold to GlaxoSmithKline), Versartis (Nasdaq: VSAR), and Novocure (Nasdaq: NVCR). He started his career at Boehringer Ingelheim Pharmaceuticals in Connecticut where he was leading development projects in oncology, inflammation and cardiovascular disease, advancing several compounds from pre-clinical to clinical stage. Roman received a PhD from MIT as well as an MBA from NYU’s Stern School of Business. He has authored or co-authored numerous publications in prestigious journals as well as issued patents.
Follow Roman Fleck:
About Janpix: Janpix operates as an oncology-focused startup.
Michael Gilman
CEO of Arrakis Therapeutics
Michael Gilman, Ph.D. has served as a member of our board of directors since November 2013. Michael Gilman is currently Chairman and Chief Executive Officer for Arrakis Therapeutics, Inc., a role he has served in since 2016, and Chief Executive Officer and Director for Obsidian Therapeutics, Inc., a role he has served in since 2016. Previously, from 2014 to 2016 Michael Gilman was Founder and Chief Executive Officer of Padlock Therapeutics, Inc. Prior to Padlock, Michael Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec Inc. from 2012 to 2013. He joined Biogen Idec Inc. in 2012 following its acquisition of Stromedix, Inc., where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, from 1999 to 2005, Michael Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Michael Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Michael Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York. He also serves on the Board of Directors of X4 Pharmaceuticals, Inc. and the Scientific Advisory Board of FutuRx, an Israeli biotech accelerator. Michael Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and an S.B. in Life Sciences from Massachusetts Institute of Technology.
Follow Michael Gilman:
About Arrakis Therapeutics, Obsidian Therapeutics: Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.
Michael Gilman
Chief Executive Officer of Arrakis Therapeutics
Follow Michael Gilman:
About Arrakis Therapeutics: Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.
Richard Murray
CEO of Jounce Therapeutics
Rich Murray is the chief executive officer of [Jounce Therapeutics](https://www.crunchbase.com/organization/jounce-therapeutics), a company that develops cancer immune-therapies to harness the immune system to attack cancerous cells and tumors. He was previously the senior vice president of biologics and vaccines at Merck. Murray holds a bachelor’s degree in microbiology from the University of Massachusetts and a PhD in microbiology and immunology from the University of North Carolina.
Follow Richard Murray:
About Jounce Therapeutics: Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
John Evans
Chief Executive Officer of Beam Therapeutics
John Evans joined Beam in 2017 as CEO, bringing significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Mr. Evans is also a Venture Partner with ARCH Venture Partners. Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals (AGIO), most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. At Agios, Mr. Evans served as IDH Portfolio Executive, providing strategic and operational leadership for a portfolio of first-in-class IDH inhibitors including IDHIFA (AG-221) and AG-120. He helped initiate and lead Agios’s landmark alliance with Celgene, resulting in over $600M of funding and investments across multiple innovative research collaborations in cancer metabolism. He also initiated and co-led Agios’s strategic expansion into rare genetic diseases of metabolism. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals as program executive for the company’s Hsp90 inhibitors. He has also worked at McKinsey & Company (Pharmaceuticals practice), MedImmune, and Bayer Pharmaceuticals. Mr. Evans holds an M.B.A. in Healthcare Management from Wharton, a Masters in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.
Follow John Evans:
About Beam Therapeutics: Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
John Evans
CEO of Beam Therapeutics
Follow John Evans:
About ARCH Venture Partners, Beam Therapeutics: Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Leila Pirhaji
Chief Executive Officer of ReviveMed
Founder and CEO at ReviveMed, experienced engineer and entrepreneur with a Ph.D. in Biological Engineering from MIT. During her PhD at MIT, Leila Pirhaji developed a pioneering machine-learning technology, which translates data from small molecules or metabolites into therapeutic solutions and was published in Nature Methods. Leila Pirhaji founded ReviveMed Startup Company to commercializes this technology, and enable developing the right therapeutics for the right patients by leveraging machine-learning and metabolomics.
Follow Leila Pirhaji:
About ReviveMed: ReviveMed is a precision-medicine platform that leverages the data from small molecules or metabolites.
Eric Kelsic
Founder & CEO of Dyno Therapeutics
Eric Kelsic is the Founder and CEO of Dyno Therapeutics. He is a graduate of Harvard University.
Follow Eric Kelsic:
About Dyno Therapeutics: Dyno Therapeutics is a biotechnology company that uses artificial intelligence for gene therapy.
Peter Van Haur
Chief Executive Officer of VitalConnect
Peter Van Haur is the Chief Executive Officer at VitalConnect.
Follow Peter Van Haur:
About VitalConnect: VitalConnect is a wearable biosensor technology for wireless hospital and remote patient monitoring.
Brad Margus
Co-founder & CEO of Cerevance
Brad Margus currently serves as Co-Founder and Chief Executive Officer of Cerevance, a drug discovery company focused on brain diseases with sites in Massachusetts and the United Kingdom. From 2009-2012, as Chief Executive Officer of Envoy Therapeutics, he raised $8 million from investors, employed a unique technology to discover new compounds for brain diseases, and sold the company within three years for $140 million. From 2000 to 2007, Brad Margus was the Chief Executive Officer of Perlegen Sciences, a leader in analyzing genetic variation that raised $257 million from investors, exceeded $100 million in revenues, and identified diagnostic markers for disease risk and drug response. Brad Margus has been a member of numerous government advisory committees as well as corporate and nonprofit boards. He currently serves on the Boards of Second Genome, Presage Biosciences and the non-profit A-T Children’s Project. Additionally, he serves as the Chair of the Network for Excellence in Neuroscience Clinical Trials External Oversight Board at the NIH. Brad Margus obtained his M.B.A. from Harvard Business School.
Follow Brad Margus:
About A-T Children’s Project, Cerevance: Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
Frank Reynolds
Chairman of the Board, CEO, CFO, CSO & Co-Founder of PixarBio
Follow Frank Reynolds:
About PixarBio: PixarBio Corp is a specialty Biotechnology company focused on pre-clinical and commercial development of new products.
Frederic Chereau
President & CEO of LogicBio Therapeutics
Frederic Chereau joined LogicBio Therapeutics as President & CEO in 2016.
Follow Frederic Chereau:
About LogicBio Therapeutics: LogicBio Therapeutics is a gene therapy startup
Joseph K. Jachinowski
President and Chief Executive Officer of Mevion Medical Systems
Joe comes to Mevion Medical Systems with a distinguished 28-year track record of successfully developing products and building companies in the field of radiation therapy for cancer. He was most recently Executive Vice President of Elekta AB, a leading supplier of radiation therapy equipment, and CEO of Elekta Holdings with overall responsibility for all of Elekta’s North American operations. Prior to Elekta, he co-founded IMPAC Medical Systems, and served as its President and CEO through its initial public offering and culminating in its sale to Elekta in 2005. Joe began his career at Varian Medical Systems, where he was responsible for leading the team that developed their innovative linear accelerator products in the 1980s.
Follow Joseph K. Jachinowski:
About Mevion Medical Systems: Mevion Medical Systems develops radiation therapies for the treatment of cancer.
Justin Hanes
Founder, Director & Former CEO of GrayBug
Justin Hanes received a B.S. in Chemical Engineering from UCLA in 1991 and Ph.D. in Chemical Engineering from MIT in 1996. He did postdoctoral training in Oncology and Neurosurgery at the Johns Hopkins University School of Medicine in 1996-1998. He is a full Professor at Johns Hopkins University, with appointments in the Departments of Ophthalmology, Biomedical Engineering, Chemical & Biomolecular Engineering, Environmental Health Sciences, Neurosurgery and Oncology. He is the Director of the Center for Nanomedicine at the Johns Hopkins University School of Medicine, where he leads a laboratory of more than 40 scientists and engineers. He also serves on the Executive Committee and as Director of Therapeutics for the Institute for NanoBioTechnology at Johns Hopkins. He has published widely and is an inventor on more than 15 patent families, many of which have been licensed to industry. He has given more than 100 invited lectures and has received numerous honors and awards , including being named among the World’s Top 100 Young Innovators and Leaders in Technology and Business, by the MIT Technology Review in 2003. He was also named a Global Young Leader by the U.S. National Academy of Sciences, and selected as a representative of the U.S. to attend the Meeting of the New Champions at the World Economic Forum in Tianjin, China in 2008. He currently serves on the scientific advisory board for Genentech, Inc.’s Drug Delivery Division and is a founder and director of Kala Pharmaceuticals, where he also serves as the Chair of the Scientific Advisory Board.
Follow Justin Hanes:
About GrayBug, Johns Hopkins University School of Medicine, Kala Pharmaceuticals, Spiral Therapeutics, The Johns Hopkins University: GrayBug focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases.
Richie Bavasso
Founder and CEO of nQ Medical
Mr. Bavasso is one of the early pioneers of use of digital media, devices and the web as tools to support pharmaceutical sales and marketing strategies and tactics. Since 1999, he has worked with top 25 Pharma clients globally to introduce the Closed Loop Marketing (CLM) function. He has set procedure and precedent in the areas of sales force effectiveness, business-rule driven content management, multichannel marketing, and mobile technology. A frequent speaker at industry conferences and events, Mr. Bavasso serves as an advocate for the industry in promoting digital conversation as integral to the various enterprise functions within pharma and the medical community. Prior to his seven years as co-founder and President of Exploria SPS, Mr. Bavasso served for sixteen years as CEO of Pharmedica Holdings, LLC, and President of its INFLUENT Division, at the time one of the largest medical education companies in the world. He built Pharmedica holdings from its start as a meetings planning company in 1992, doubling its revenues each year until its sale in 2001. This growth included an ACCME accredited entity (Center for Medical Education, LLC), a digital content division (Influent, LLC), and a call center (ContextMedicus, LLC). He opened offices in California, Connecticut, Illinois, and North Carolina. After his three-year earn out, Bavasso partnered to co-found Exploria SPS, LLC, as the mobile devices division of Exploria, Inc. Within three years, Exploria SPS became the market leader for CLM with offices in Connecticut and France and currently licenses software in 33 countries and 18 languages. Mr. Bavasso’s introduction of CLM and subsequent influence over the growth and expansion of CLM globally led to his recognition in 2007, by PharmaVoice magazine as one of the top 100 most influential people in pharma. Foreseeing the trends in Pharma that have impacted its selling model and the changing influence dynamic of payors on prescribing, Mr. Bavasso incubated a new and disruptive concept meant to serve as the transaction-fed, new marketplace for healthcare. This led to the incorporation of RIMEDIO, Inc. in October 2012 intent on reshaping the dynamic of how healthcare interacts and transacts to achieve mutual stakeholder objectives. RIMEDIO leverages the power of social utilities with eCommerce, content management and communications tools to consummate transactions between healthcare stakeholders. He is currently co-founder and CEO of nQ Medical, Inc., a machine learning computational biomarker company leveraging keyboard data to manage neuromotor diseases. Everyone has a unique typing signature. Research has revealed that the way we interact with computers and mobile devices can reveal with startling accuracy the presence of certain neuro-motor diseases. This Massachusetts Institute of Technology discovered/Michael J. Fox Foundation validated artificial intelligence tool (neuroQWERTY) has opened a broad opportunity to better diagnose diseases, track disease progression, and monitor medication effectiveness and symptoms. Mr. Bavasso is also a licensed hospital administrator having served from 1981 to 1992 leading two health care systems in New England. A graduate of Pepperdine University, Malibu, CA, with a Bachelor of Science degree in business administration, he received his MBA in health care management and finance from Bryant University, Smithfield, RI.
Follow Richie Bavasso:
About nQ Medical: nQ Medical is a neurotechnology company allowing Data Defined Disease Management via digital biomarkers using AI.
Estuardo Aguilar-Cordova
Chairman and Chief Executive Officer of Candel Therapeutics
Estuardo Aguilar-Cordova is a co-founder of Candel Therapeutics and has been the chairman and CEO since 2002. He has more than 30 years of experience in the fields of biotherapeutics, cancer research and drug development, including serving as principal or co-investigator in more than 25 clinical trials ranging from Phase I to Phase III. Prior to moving into his role at Candel, Estuardo Aguilar-Cordova held academic positions for nearly two decades. Most recently, he was deputy director of the Harvard Gene Therapy Initiative at Harvard Medical School in Boston and was a faculty member in Pediatrics, Hematology-Oncology at Baylor College of Medicine in Houston. He has served on many national oversight committees, including roles as chairman and member of the NIH Recombinant Advisory Committee (RAC), as a consultant to the FDA Biological Response Modifiers Advisory Committee (BRMAC), and as a member of the Vaccine and Related Products Advisory Committee (VRPAC). Estuardo Aguilar-Cordova has also held other appointments including president of the Latin American Gene Therapy Society. Estuardo Aguilar-Cordova has published more than 80 peer-reviewed scientific publications and book chapters, is on the editorial board of various professional journals and is an inventor on several patent applications. A native of Guatemala, Estuardo Aguilar-Cordova completed his undergraduate studies in Biology at California State University, Bakersfield; Medicine, at Universidad Francisco Marroquín in Guatemala City; and Ph.D. in Molecular Genetics at the University of California at Davis.
Follow Estuardo Aguilar-Cordova:
About Candel Therapeutics: Candel Therapeutics develops cancer immunotherapies designed to improve the lives of cancer patients and their families.
David Meeker
Chairman, President & Chief Executive Officer of Rhythm Pharmaceuticals
Follow David Meeker:
About Rhythm Pharmaceuticals, Sanofi Ventures: Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Kate Rumrill
President and CEO of Ablative Solutions
Kate brings 27 years of experience in the Medical Device and Pharmaceutical Industry. Previously she held the position of Vice President, Global Clinical and Medical Affairs at Covidien. She has extensive experience in product development in the CNS space through her time at Aspect Medical Systems and Eli Lilly & Company. Kate first joined NeoSync in 2010, leading the company’s clinical and regulatory activities, and later rejoined as President and CEO in April 2015. She holds a BS degree in both Biology and Psychology from the State University of New York.
Follow Kate Rumrill:
About Ablative Solutions: Ablative Solutions is a medical device firm that offers an alternative to surgical renal denervation for treating hypertension.
Stephen J. Gatto
Chairman and Chief Executive Officer of Entrinsic Bioscience
Stephen J. Gatto founded Myriant’s predecessor company in 2004 and formed Myriant in 2009. He has been involved in the biotechnology industry for over 19 years, founding a successful biofuels company and serving on numerous Presidential, Congressional and US DOE/USDA committees. At BC International (now Verenium), Stephen Gatto, in cooperation with Dr. Lonnie Ingram and the University of Florida, spearheaded the development of novel technology for the commercial production of ethanol from cellulose (patent number 5,000,000). Successful pilot operations led to licensing of the technology to two multinational companies. In 2000 and 2002, Stephen Gatto was appointed by both the Clinton and Bush Administrations to the Biomass Research & Development Technical Advisory Committee. He was also appointed to a Biofuels Ad-hoc Committee chaired by Senator Dianne Feinstein and assisted in the drafting of key aspects of the Energy Policy Act of 2005. Currently, Stephen Gatto is on the board of directors for BIO, the world’s largest biotechnology organization, serving on the Industrial and Environmental (I&E) section governing board.
Follow Stephen J. Gatto:
About Entrinsic Bioscience: Entrinsic Bioscience leverages gold standard science and game-changing amino acid technology.
Kevin Hershberger
President & Chief Executive Officer of Lumicell
Follow Kevin Hershberger:
About Lumicell: Lumicell is a biotechnology company that develops and markets image-guided cancer surgery solutions.
David Platt
CEO of Boston Therapeutics
David Platt, Ph.D., Boston Therapeutics founder and CEO.
Follow David Platt:
About BioXyTran, Boston Therapeutics, Oxygen Therapy: Boston Therapeutics develops and commercializes novel compounds for unmet medical needs in the areas of diabetes and inflammatory diseases.
Diego Miralles
CEO of Vividion Therapeutics
Diego Miralles is the Chief Executive Officer at Vividion Therapeutics.
Follow Diego Miralles:
About Flagship Pioneering, Laronde, Vividion Therapeutics: Vividion is a developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses.
Jonah Kallenbach
Co-founder & CEO of Reverie Labs
Jonah Kallenbach is a Co-Founder and CEO at Reverie Labs. He attended Harvard University.
Follow Jonah Kallenbach:
About Reverie Labs: Reverie Labs is a machine learning-driven pharma company.
Robert E. Ward
Chairman and Chief Executive Officer of Eloxx
Robert (Bob) E. Ward is the Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals, Inc. (“Eloxx”). He previously served as the Chief Executive Officer and President at Radius Health, Inc. (NASDAQ: RDUS) successfully completing the initial public offering that became the top performing IPO; raised over $780M from private and public sources; achieved FDA approval and launch of the new drug TYMLOStm injection while gaining Fast Track development status for the Elacestrant oncology program. Prior to joining Radius, Robert Ward held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Robert Ward has been a Director of Akari Therapeutics, Plc since October 14, 2016 where he chairs the Governance Committee. He served as a Director of Radius from December 2013 until July 16, 2017. Robert Ward serves as a Director of the Massachusetts High Technology Council. Robert Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the John Hopkins University School of Medicine.
Follow Robert E. Ward:
About Eloxx: Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates.
Ajikumar Parayil
CEO & Founder of Manus Bio
Follow Ajikumar Parayil:
About Manus Bio, Mirakel Technologies: Manus Bio makes nature accessible and affordable for a growing society.
Eddie Martucci
Co-Founder and CEO of Akili Interactive Labs
Dr. Martucci is a Senior Associate at PureTech Ventures, and is part of the founding team of Akili Interactive Labs, Appeering, and Vedanta Biosciences. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation. Dr. Martucci completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on the rational design of novel allosteric inhibitors for a pathogenic parasite. He led a research project that characterized a potential enzyme drug target and identified two novel chemical scaffolds as potent proof-of-concept compounds for novel antiparasitic therapy. During his graduate work, he received NIH training grants in both Chemical Biology and Parasitology. Dr. Martucci received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.
Follow Eddie Martucci:
About Akili Interactive Labs, PureTech Health: Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games.
Tim Guilliams
Founder, CEO of Healx
Tim is a social entrepreneur passionate about delivering the next generation of therapeutics to rare disease patients in need. He is the Founder and Chief Executive of Healx and the Co-Founder and Chair of the Cambridge Rare Disease Network (CRDN), a charity aiming to foster dialogue and awareness around rare diseases in Cambridge, UK. Prior to Healx and CRDN, Tim worked on University-Industry interactions and cluster dynamics in the area of Life Sciences for the UK Government Department for Business, Innovation and Skills (BIS). He obtained his PhD in the field of Biophysical Neuroscience at the University of Cambridge, where his research related to the development of antibody fragments as novel biophysical and therapeutic tools for Parkinson’s disease. As a PhD student, Tim co-founded multiple successful student societies, including the Cambridge University Science and Policy Exchange (CUSPE), and was involved with Innovation Forum, Oxbridge Biotech Roundtable (OBR) and the Cambridge University Technology and Enterprise Club (CUTEC). He is also a Junior Associate Fellow of the Centre for Science and Policy (CSaP). Before moving to Cambridge, he obtained an MEng & BEng in Bio-Engineering from the University of Brussels (VUB).
Follow Tim Guilliams:
About Healx: Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Jasbir Seehra
CEO of Keros Therapeutics
Jasbir Seehra is the founding CEO of Keros Therapeutics. Jas worked with the academic founders and Pontifax in putting together the strategy and in-licensing of the founding technology. Jas brings more than 30 years of scientific, strategic and operational experience in Biotech industry. Prior to Keros, Seehra was the CSO at Ember Therapeutics, founded by Third Rock Ventures. In 2003, Jas co-founded Acceleron Pharma, focused on biologics inhibiting the TGFb superfamily and served as CSO to the end of 2010. Jas hired the research team that discovered multiple products and manufacturing teams and oversaw the discovery and development of multiple products targeting muscle strength, bone loss and anemia. As founder and member of the executive team, Jas helped raise more than $200M capital from venture fund and corporate partnerships with Celgene and Shire.
Follow Jasbir Seehra:
About Keros Therapeutics: Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.
Andrew Lynn
Chief Executive Officer of Fluidic Analytics
Andrew Lynn is an entrepreneur and executive with a focus on early-stage life-sciences and technology opportunities. Andrew founded the regenerative medical device company Orthomimetics Ltd, based on his PhD thesis at the University of Cambridge. He then led the company as CEO from incorporation to successful trade-sale exit. During his tenure at Orthomimetics, the company raised £7.5 million in venture capital and grant funding, established commercial-scale manufacturing capabilities and brought the flagship product through pilot clinical trials to market. In 2009, he led a process that culminated in the successful sale of the company. Andrew Lynn subsequently led solid-state-lighting venture CamGaN Limited as CEO from the commencement of operations to a successful exit in 2012. His efforts have earned him recognition in Europe as an inaugural winner of a Science|Business Academic Enterprise Award and in the US as a member of Technology Review Magazine’s TR35 list of the world’s top young innovators, leaders and entrepreneurs.
Follow Andrew Lynn:
About Fluidic Analytics: Fluidic Analytics designs, develops and manufactures tools that seek to revolutionise the way proteins are characterised.
Ian Chan
Chairman & CEO of Abpro
Chairman & CEO at Abpro.
Follow Ian Chan:
About Abpro: Abpro is a biotechnology company focused on therapeutics, diagnostics, and research.
Steven L. Hoerter
President and CEO of Deciphera Pharmaceuticals
Steven L. Hoerter has served as our Senior Vice President, Commercial since August 2011. From 2010 to 2011, Steven Hoerter was General Manager and Management Center Head at F. Hoffmann-La Roche Ltd. for the Sub-Saharan Africa and Indian Ocean Region, based in Johannesburg, South Africa. From 2005 to 2010, Steven Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s BioOncology business as Senior Director, Pipeline Development and Commercial Operations. Prior to that he worked at Chiron Corporation and Eli Lilly and Company. During Steven Hoerter’s 11-year career at Lilly, he held positions in sales, business development, marketing and business unit management in the US, Europe and Africa. Steven Hoerter has a B.A. in Russian and Political Science from Bucknell University, an M.B.A. from Tilburg University and a M.S. in Management from Purdue University.
Follow Steven L. Hoerter:
About Deciphera Pharmaceuticals: Deciphera Pharmaceuticals focuses on improving kinase inhibitor treatments.
Jim Broderick
CEO & Founder of Palleon Pharmaceuticals
Jim is a Partner on the Morgenthaler Life Sciences Team and invests in companies developing innovative therapeutic products in the biotech and medical device industries. Jim is a co-founder and Chairman at Promedior Pharmaceuticals, a company developing drugs to treat fibrotic diseases such as Idiopathic Pulmonary Fibrosis and Myelofibrosis. Jim is a co-founder and Chairman at Ra Pharmaceuticals, a biotech company developing orally available and cell permeable peptide drugs. Jim was the founding CEO and currently serves as a Board member at SetPoint Medical, a company developing implantable neurostimulation devices to treat inflammatory diseases such as Crohn’s Disease and Rheumatoid Arthritis as an alternative to drug therapy. He is an investor and board member of several other novel biotech and medical device companies, including OncoMed Pharmaceuticals (NASDAQ: OMED), the leader in the field of drugs targeting cancer cell pathways, and Spine Wave, a commercial stage company selling multiple innovative devices for minimally invasive spinal surgery. Jim opened Morgenthaler’s Boston Office in 2005 after spending several years in Silicon Valley. Jim is a graduate of MIT (Bachelors in Mechanical Engineering) and University of Massachusetts (Doctor of Medicine). Jim was a member of the Kauffman Fellows Program, a two-year educational fellowship sponsored by the Kauffman Center for Entrepreneurial Leadership designed to train future venture capitalists and leaders of high growth companies.
Follow Jim Broderick:
About Palleon Pharmaceuticals: Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.
Rodolphe Clerval
Chief Executive Officer of Coave Therapeutics
Chief Executive Officer at Coave Tx (formerly Horama).
Follow Rodolphe Clerval:
About Coave Therapeutics, Coave Therapeutics, Coave Therapeutics, ENTEROME, TcLand Expression: Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.
Iain MacLeod
Co-Founder ,CSO & CEO of Aldatu Biosciences
Iain is responsible for leading the advancement of Aldatu’s pathogen and drug resistance diagnostic technology in addition to guiding the company’s global health strategy. Iain maintains an academic appointment at the Harvard School of Public Health AIDS Initiative. He undertook his post-doctoral training at the Harvard School of Public Health, and the Botswana-Harvard AIDS Institute in Gaborone, Botswana, where he focused on HIV drug resistance. Iain holds a Ph.D. in Pathology – specializing in molecular virology – from the University of Cambridge (2008), an LL.M. in International Law, and a B.Sc. in Virology from the University of Glasgow.
Follow Iain MacLeod:
About Aldatu Biosciences, Harvard T.H. Chan School of Public Health: Aldatu Biosciences is changing infectious disease treatment paradigms through innovative diagnostic solutions.
Ed Damiano
President & CEO of Beta Bionics
Ever since his now 19-year-old son David developed type 1 diabetes at 11 months of age, Ed D. has been committed to creating and integrating closed-loop blood-glucose control technologies with a vision of building a bionic pancreas by the time his son headed off to college. Between 2005 and 2008, he and his PhD student, Firas El-Khatib, began conducting experiments in diabetic pigs in his laboratory at Boston University testing an early laptop-version of their bionic pancreas system. They then progressed with their clinical collaborators at the Massachusetts General Hospital to conduct over four years in-patient trials in adults and adolescents with T1D. Over the past five years, his team at Boston University, along with his clinical collaborators, have conducted over a dozen outpatient and home-use clinical trials in adults and children with type 1 diabetes testing a mobile version of their bionic pancreas, which ran on an iPhone. This effort ultimately led to the development of the iLet bionic pancreas system. In 2015, Ed and his wife Toby Milgrome, along with Firas El-Khatib and Ed and Serafina Raskin, founded Beta Bionics, Inc. as a Massachusetts public benefit corporation with the goal of bringing the iLet through final clinical trials, regulatory approval and into the hands of people with type 1 diabetes. Ed Damiano is a Professor of Biomedical Engineering at Boston University and has held that role since 2004. He is also President and CEO of Beta Bionics. His expertise and training are in the areas of mechanical and biomedical engineering and applied mathematics.
Follow Ed Damiano:
About Beta Bionics: Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet.
